Answers are grounded in this paper and cite their sources.
Randomized trial evaluates weight loss in individuals with obesity, indicating effective interventions with CT-388.
Introduction and Objective: This trial (NCT06525935) evaluated the efficacy, safety, and dose-response of CT-388 in participants (pts) with overweight/obesity without T2D. Methods: This was a double-blind, placebo-controlled, multicenter trial which enrolled pts with BMI ≥30 kg/m² or BMI ≥27kg/m² with ≥1 obesity-related conditions, of whom 467 were randomized (1:1:1:1:1:1) to treatment with once-weekly subcutaneous CT-388 (target doses: 4, 8, 12, 16, or 24 mg) or volume-matched placebo (Pbo) for 48 weeks. Primary endpoint was % WL from baseline (BL) to Week (W) 48, analyzed using a mixed model for repeated measures based on an ‘efficacy’ estimand. Results: Pts in the study had a mean (SD) age of 49 (13.1) years, BMI of 38 (6.9) kg/m²; 71% were White, 68% women and ~50% had prediabetes (per ADA). Figure shows WL (%) effect of CT-388 vs Pbo. With CT-388 (24 mg) at W48: no WL plateau was observed, 95.7% of pts achieved ≥5% WL, 87.0% ≥10% WL, 47.8% ≥20% WL, and 26.1% ≥30% WL. Among pts with prediabetes at BL, 73% of CT-388 24 mg achieved normoglycemia (vs 7.5% on Pbo). The rate of treatment discontinuations from adverse events were low. GI events were the most frequent. Conclusion: CT-388 demonstrated clinically meaningful, statistically significant dose-dependent WL of up to 22.7% (W48) and safety/tolerability profile consistent with the incretin class. Disclosure I. Lingvay: Consultant; Current; Aadvarak Therapeutics, Abbvie, Alveus Therapeutics, Amgen, Antag Therapeutics, Arrowhead Pharmaceuticals, Astra Zeneca, Baim Institute, Bain Capital, Bayer, Betagenon AB, Bioio Inc., Biomea, Boehringe. Research Support; Current; Novo Nordisk A/S, Dexcom, Inc., Boehringer Ingelheim International GmbH. Consultant; Current; Eli Lilly, Genentech, Janssen/J&J, Juvena, Keros Therapeutic, Inc, Mediflix, Metsera, Neurocrine, Novo Nordisk, Penguin Bio, Pfizer, Regeneron, Response Pharmaceutical, Roche, Sanofi, Shionogi, Skye B, Tenvie, TERNS Pharma, Verdiva Bio, Viking Therapeutics, and Zealand Pharma. A. Jastreboff: Other - multi-center trial; Current; Amgen, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Rhythm Pharmaceuticals. Other - scientific advisory board; Current; Amgen, AstraZeneca, Boehringer Ingelheim, Biohaven, Eli Lilly, Metsera, Novo Nordisk, Pfizer, Regeneron, Roche/Genentech, Scholar Rock, Structure Therapeutics, Syntis Bio, WW International, Zealand Ph. Other - academic co-founder; Current; State 4 Therapeutics. D. Lender: None. H.E. Bays: Research Support; Current; 89bio, Inc., Alon Medtech/Epitomee, Altimmune, Amgen Inc., AstraZeneca, Bioage, Boehringer Ingelheim International GmbH, Carmot Therapeutics, Inc., Eli Lilly and Company, Graviton, Merck & Co., Inc., Metsera, Novartis Pharmaceuticals Corporation, Novo Nordisk, Pfizer Inc., Regeneron Pharmaceuticals Inc., Birdrock, Tern, Viking Therapeutics, Vivus, Zomagen. Advisory Panel; Current; 89bio, Inc., Altimmune, Amgen Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Regeneron Pharmaceuticals Inc., Rivus, Zomagen, zyversa. Research Support; Current; Kailera. Advisory Panel; Current; Merck & Co., Inc. M. Chakravarthy: Employee; Current; Genentech, Inc. C. le Roux: Advisory Panel; Current; Novo Nordisk, Lilly, Amgen Inc., Boehringer Ingelheim International GmbH, Pfizer Inc., AstraZeneca, Roche Pharmaceuticals, Herbalife International of America, Inc., Arrowhead Pharmaceuticals, Inc., Medtronic. E. Shearer-Kang: Employee; Current; Genentech, Inc. G. Palermo: Employee; Current; Roche Pharmaceuticals. J. Willis: Employee; Current; Genentech, Inc. A. Steinberg: Employee; Current; Genentech, Inc. Employee; Ended; Carmot Therapeutics, Inc. S.C. Sharp: None. S.B. Bollepalli: None. K.T. Kim: Research Support; Current; Genentech, Inc., Amgen Inc., Eli Lilly and Company, GlaxoSmithKline plc., Sanofi, AstraZeneca, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc.
No takes yet. Share an insight, caveat, or question.
Lingvay et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: